Takeda has updated its financial results to reflect costs it could incur after losing an antitrust lawsuit concerning its laxative drug Amitiza.
June 8, 2026 07:01 AM EDT
Takeda says it expects to take $2.5B hit after Amitiza antitrust verdict, with plans to appeal
Takeda has updated its financial results to reflect costs it could incur after losing an antitrust lawsuit concerning its laxative drug Amitiza.
In May, the …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Takeda takes $2.5B legal charge after pay-for-delay verdict, swings to loss for '25
‘Not simply saving cost’: Inside Astellas CEO’s 5-year strategy to counter Xtandi’s patent cliff
AstraZeneca’s ‘extensive’ obesity drug push; $125M for ultrasound-aided genetic medicine
Takeda’s $4B TYK2 drug tops Bristol Myers’ Sotyktu in head-to-head test
Lilly, Boehringer to slash at least $1B each from planned investments in Germany
ADC Therapeutics' shares plummet after patient deaths in trial of Zynlonta
Otsuka showcases kidney drug data; Pfizer cuts an AI deal
Takeda faces nearly $885 million jury verdict in AMITIZA antitrust case and plans post-trial motions and appeal.
A recent antitrust verdict has prompted Takeda to revise its 2025 financials, putting the drugmaker at a 152 billion Japanese yen…
Takeda confirmed it would appeal the outcome, stating that the case “lacks merit”.
Takeda plans to appeal after a federal jury found it liable in a landmark pay-for-delay antitrust case and ordered the Japanese…
Attorneys at Hagens Berman Announce $474M Win in Amitiza Jury Trial Against Takeda
Japanese drugmaker was accused by US pharmacies, retailers of 'pay-for-delay' scheme
